文献速递儿科与产科急症重症综合管理与镇静镇痛

儿科行为健康患者的静脉与肌注化学约束治疗:来自全国急诊科样本的结果

Treatment of pediatric behavioral health patients with intravenous and intramuscular chemical restraints: Results from a nationwide sample of emergency departments.
PubMed 文献 · Acad Emerg Med · 2023-06-19
一句话结论630384例8-17岁行为健康急诊患儿中4.8%接受静脉/肌注化学约束,年龄13-17岁及焦虑、破坏性障碍等诊断与更高约束几率相关,且医院本身对是否约束影响很大。

该回顾性研究基于Premier Healthcare Database,纳入2018年1月1日至2020年12月31日822家急诊科收治的8-17岁、带行为健康出院诊断的630384例病例,主要结局为静脉/肌注化学约束药物的使用。结果显示4.8%的病例接受了静脉/肌注化学约束;校正患者与医院因素后,13-17岁(AOR 1.53,95%CI 1.48-1.58)、焦虑障碍(AOR 1.69,95%CI 1.64-1.74)、破坏性障碍(AOR 1.61,95%CI 1.53-1.69)、自杀/自伤(AOR 1.3,95%CI 1.26-1.34)、物质使用(AOR 1.24,95%CI 1.20-1.28)、双相障碍(AOR 1.23,95%CI 1.17-1.30)及复杂合并症(AOR 1.32,95%CI 1.26-1.39)与更高约束几率相关。校正后医院层面因素对约束几率影响的中位OR为1.43(95%CI 1.40-1.47),提示就诊医院强烈影响是否使用化学约束。

要点

  • 8-17岁行为健康急诊患儿中4.8%接受静脉/肌注化学约束(630384例中的比例)。
  • 13-17岁较更小年龄约束几率更高(AOR 1.53,95%CI 1.48-1.58)。
  • 焦虑障碍(AOR 1.69,95%CI 1.64-1.74)与破坏性障碍(AOR 1.61,95%CI 1.53-1.69)约束几率最高。
  • 自杀/自伤(AOR 1.3,95%CI 1.26-1.34)、物质使用(AOR 1.24,95%CI 1.20-1.28)、双相障碍(AOR 1.23,95%CI 1.17-1.30)及复杂合并症(AOR 1.32,95%CI 1.26-1.39)也与更高约束几率相关。
  • 校正患者与医院因素后,医院对约束几率影响的中位OR为1.43(95%CI 1.40-1.47)。

适用人群与场景

  • 年龄8-17岁、在822家急诊科就诊且带行为健康出院诊断的儿科患者,数据来自Premier Healthcare Database,时间为2018年1月1日至2020年12月31日。

研究设计与关键结果

  • 研究类型为回顾性研究,纳入2018年1月1日至2020年12月31日822家急诊科的630384例8-17岁行为健康出院诊断患者,主要结局为静脉/肌注化学约束药物的使用。
  • 630384例中4.8%接受了静脉/肌注化学约束。
  • 校正患者与医院因素后,13-17岁与更高约束几率相关(AOR 1.53,95%CI 1.48-1.58)。
  • 焦虑障碍(AOR 1.69,95%CI 1.64-1.74)、破坏性障碍(AOR 1.61,95%CI 1.53-1.69)、自杀/自伤(AOR 1.3,95%CI 1.26-1.34)、物质使用(AOR 1.24,95%CI 1.20-1.28)、双相障碍(AOR 1.23,95%CI 1.17-1.30)及复杂合并症(AOR 1.32,95%CI 1.26-1.39)均与更高约束几率相关。
  • 校正患者与医院因素后,医院层面因素对约束几率影响的中位OR为1.43(95%CI 1.40-1.47)。

证据类型、等级与局限

  • 证据类型:回顾性研究,基于Premier Healthcare Database的822家急诊科数据。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文结论指出,年龄和某些行为健康诊断与儿科行为健康急诊就诊期间接受静脉/肌注化学约束相关,且是否使用化学约束强烈受就诊医院影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Behavioral health crises in pediatric emergency department (ED) patients are increasingly common. Chemical restraints can be utilized for patients who present imminent danger to self or others. We sought to describe the use of intravenous (IV)/intramuscular (IM) chemical restraints for pediatric behavioral health ED patients across a nationwide sample of hospitals and describe factors associated with restraint use.

METHODS: This was a retrospective study of patients ages 8-17 treated at 822 EDs contributing data to the Premier Healthcare Database between January 1, 2018, and December 31, 2020, with a behavioral health discharge diagnosis. The primary outcome was the use of IV/IM chemical restraint medication. We developed a hierarchical model to examine patient and hospital-level factors associated with treatment with IV/IM chemical restraint medications.

RESULTS: Of 630,384 cases, 4.8% received IV/IM chemical restraint. Patient factors associated with higher odds of chemical restraint were older age (ages 13-17 years [adjusted odds ratio {AOR} 1.53, 95% confidence interval {CI} 1.48-1.58]), anxiety disorders (AOR 1.69, 95% CI 1.64-1.74), disruptive disorders (AOR 1.61, 95% CI 1.53-1.69), suicide/self-injury (AOR 1.3, 95% CI 1.26-1.34), substance use (AOR 1.24, 95% CI 1.20-1.28), and bipolar disorder (AOR 1.23, 95% CI 1.17-1.30). Participants with complex comorbidities were more likely to receive chemical restraint (AOR 1.32, 95% CI 1.26-1.39). After patient and hospital factors were adjusted for, the median OR indicating the influence of the individual hospital on the odds of chemical restraint was 1.43 (95% CI 1.40-1.47).

CONCLUSIONS: We found that age and certain behavioral health diagnoses were associated with receipt of IV/IM chemical restraint during pediatric behavioral health ED visits. Additionally, whether a patient was treated with chemical restraints was strongly influenced by the hospital to which they presented for treatment.

来源:Acad Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Tang AS, Shieh MS, Pekow PS, et al. Treatment of pediatric behavioral health patients with intravenous and intramuscular chemical restraints: Results from a nationwide sample of emergency departments. Acad Emerg Med. 2023. PMID: 37259900. doi:10.1111/acem.14754

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。